MedTrace Logo

Bryophyllum vs. Nifedipine

NCT00391339 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2006-10-23

No results posted yet for this study

Summary

In a prospective, randomised study the efficacy and tolerability of bryophyllum p. (p.o) vs. nifedipine (p.o) will be proofed in a defined group of pregnant women with threatened preterm labour.

Conditions

  • Tocolysis

Interventions

DRUG

Bryophyllum p.

Sponsors & Collaborators

  • Weleda AG

    lead INDUSTRY

Principal Investigators

  • Roland Zimmermann, Prof. Dr. med. · Department of Obstetrics, University Zuerich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-30
Completion
2008-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00391339 on ClinicalTrials.gov